TRACON Pharmaceutical (TCON) Makes Presentations at AASLD Meeting; Includes Endoglin Antibody Data

November 14, 2016 6:28 AM EST
Get Alerts TCON Hot Sheet
Trade TCON Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

TRACON Pharmaceuticals (Nasdaq: TCON) presented data at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting, taking place November 11-15 in Boston, MA.

Preclinical data were presented from two separate liver fibrosis models in a poster presentation entitled, “Endoglin Antibody Reduces the NAFLD Activity Score in the STAM Model of NASH and Reduces Liver Fibrosis Following Carbon Tetrachloride Treatment.” Highlights include:

  • Treatment with an endoglin antibody significantly decreased the percentage of the liver fibrosis area induced by carbon tetrachloride. A group of mice treated with endoglin antibody demonstrated lower collagen deposition with less frequent formation of bridging fibrosis than the isotype-matched and disease control groups.
  • Treatment with endoglin antibodies significantly reduced the non-alcoholic fatty liver disease (NAFLD) activity score (NAS) in a model of non-alcoholic steatohepatitis (NASH), known as the STAMTM model. Endoglin antibodies demonstrated hepatoprotective, anti-inflammatory and anti-fibrotic effects. In addition, an endoglin antibody that competitively inhibited bone morphogenic protein (BMP) binding to endoglin more effectively reduced the NAS, suggesting that inhibition of BMP function is an important mechanism of action of endoglin antibodies in models of fibrosis.

The poster also highlighted a marked reduction in cutaneous neurofibromatosis in a sarcoma patient following dosing with TRACON’s TRC105 and Votrient® (pazopanib) in a Phase 2 clinical trial, suggesting the potential of an endoglin antibody as an effective treatment for patients with fibrosis.

The poster is available on TRACON’s website at

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment